UNSPSC 51263302: Butamoxane

This classification denotes an adrenergic antagonist with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7725983GSD, chemically known as 1,4-benzodioxan-2-methylamine, n-butyl- but generally known as butamoxane, which bears US NIH Compound Identifier 20504. European Medicines Agency schedules Butamoxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06002MIG.

UNSPSC 51263302 Butamoxane, a Commodity code, covers pharmaceutical products and related health-supply acquisitions procured by state and local health agencies, though the recent opportunities tagged to this code show a mismatch with its nominal scope. The Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems targets opioid-response supplies rather than butamoxane specifically, and the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions addresses pharmacy benefit program structure and contracting relationships rather than a discrete pharmaceutical product. State and local health departments, county health agencies, and state pharmacy benefit programs drive solicitations in this space, with acquisitions ranging from emergency-response medications delivered on fixed schedules to exploratory procurement for pharmacy program redesign.

Seminole County's IFB (IFB60459723LAS), posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping and delivery costs and subject to E-Verify and drug-free workplace compliance. The Texas Health and Human Services Commission's RFI (HHS0017013), posted April 3, 2026, gathered vendor capabilities on direct-to-manufacturer prescription contracting models for state employee and retiree pharmacy programs, signaling the state's intent to reshape pharmacy benefit procurement away from traditional PBM intermediaries. The geographic activity centers on Florida and Texas. The code shows limited recent volume under its stated scope; bidders should verify whether opportunities truly target butamoxane or other pharmaceuticals before committing resources.